ProStrakan receives UK approval for sublingual fentanyl
This article was originally published in Scrip
ProStrakenhas received a UK marketing approval for its fast-dissolving sublingual tablet, Abstral (licensed fromOrexo), in the UK, its second market. The product was launched recently in its first market, Sweden, the reference member state. Orexo received a milestone payment of $1 million following the UK marketing approval.
You may also be interested in...
The UK’s Artios has linked up with Merck KGaA in a potentially multi-billion dollar deal to collaborate on discovering and developing up to eight oncology drug targets associated with DNA damage response processes, and is also progressing its own lead compounds through its pipeline.
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.